Business · 07/06/2024Updated: 10/17/2026 · 1 min read
FDA Renews Obstetrics, Reproductive and Urologic Drugs Advisory Committee for 2 Years
The FDA has renewed the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on March 23, 2026.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →